Literature DB >> 9516979

Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression.

R D Meng1, H Shih, N S Prabhu, D L George, W S el-Deiry.   

Abstract

Oncoprotein MDM2 inhibits p53-dependent cell cycle arrest and apoptosis. MDM2-overexpressing human cancer cell lines (n = 3) were found to be resistant to growth inhibition after infection by p53-expressing adenovirus (Ad-p53), as compared to low MDM2-expressing tumors (n = 3), in vitro. The growth of MDM2-overexpressing tumors, however, was inhibited by p21-expressing adenovirus (Ad-p21) infection, and the cyclin-dependent kinase-inhibitory region of p21 was sufficient to bypass the MDM2-p53 feedback loop. The phosphorylation state of Rb correlated with the response to either p53 or p21 gene therapy. MDM2-overexpressing cancer cells infected by Ad-p21 also developed a quiescent large-cell morphology. The results suggest that MDM2-mediated resistance to p53 may be bypassed by p21 and that the Rb phosphorylation state may predict the effects on growth after Ad-p53 or Ad-p21 infection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9516979

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  3 in total

1.  Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic catastrophe in paclitaxel (taxol)-exposed cells.

Authors:  Timothy F Burns; Peiwen Fei; Kimberly A Scata; David T Dicker; Wafik S El-Deiry
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

2.  Wild-type p53-mediated down-modulation of interleukin 15 and interleukin 15 receptors in human rhabdomyosarcoma cells.

Authors:  C De Giovanni; P Nanni; A Sacchi; S Soddu; I Manni; G D'Orazi; S Bulfone-Paus; T Pohl; L Landuzzi; G Nicoletti; F Frabetti; I Rossi; P L Lollini
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

3.  A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin.

Authors:  H-J Tang; D Qian; V K Sondak; S Stachura; J Lin
Journal:  Br J Cancer       Date:  2004-03-22       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.